2012 Proves to be Strong Year for IVIG Distribution, Despite Market Conditions

Share Article

Strategic focus and enhanced partnerships create record distribution trend for specialty biotech distributor.

BDI Pharma's Columbia, SC Headquarters

Whether through reimbursement support, education and physician programs, or through our growing partnerships in the Specialty Pharmacy arena, BDI presents a substantive and unique value which our customers have acknowledged and embraced.

BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced that the company’s distribution of intravenous immune globulin (IVIG) is tracking greater than seventy-six percent (76%) ahead of the volume distributed by BDI during the same time period in calendar year 2011.

IVIG is a sterile solution of concentrated antibodies extracted from healthy donors which is administered into a vein. IVIG infusion therapy is used to treat disorders of the immune system, such as ITP (Immune Thrombocytopenic Purpura) and PID (Primary Immune Deficiency), disorders of the neurological system, such as CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) or to boost immune response to serious illness, and to treat immunosuppressed recipients of bone marrow transplants.

The significant increase in IVIG sales and distribution, as well as the consistent overall growth for BDI Pharma, is the result of the company’s dedicated focus on the end user – not simply on the sale of a product to a healthcare provider. “More than a product and a price is not only our motto at BDI Pharma; it is the philosophy behind each one of the corporate strategies, programs and services designed for our customers” stated Claude Ferry, Vice President of Sales for BDI Pharma. “Whether through reimbursement support, education and physician programs, or through our growing partnerships in the Specialty Pharmacy arena, BDI presents a substantive and unique value which our customers have acknowledged and embraced.”

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for comprehensive reimbursement services -- bdiaccess.com; specialty veterinarians -- 4legpharma.com; product consignment -- consignadvantage.com; flu pre-booking and general vaccine ordering -- securivax.com; and purchasing programs -- securigam.com and qoreprogram.com round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma’s portfolio includes branded and generic specialty biopharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brad Davis
Visit website